{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:22:22Z","timestamp":1791498142369,"version":"4.3.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Institutes of Health, Department of Health and Human Services"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.vaccine.2014.02.021","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T14:23:24Z","timestamp":1395757404000},"page":"2916-2926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Systematic evaluation of in vitro and in vivo adventitious virus assays for the detection of viral contamination of cell banks and biological products"],"prefix":"10.1016","volume":"32","author":[{"given":"James","family":"Gombold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Karakasidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Niksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Podczasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitti","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini","family":"Sane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renita","family":"Johnson-Leva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Sadoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Minor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Sheets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.02.021_bib0005","article-title":"Additional standards: poliovirus vaccine, live, oral","author":"Porterfield","year":"1960","journal-title":"Federal Register Doc. Nov. 23"},{"issue":"6","key":"10.1016\/j.vaccine.2014.02.021_bib0010","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1586\/14760584.3.6.633","article-title":"Vaccine cell substrates 2004","volume":"3","author":"Sheets","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.02.021_bib0015","unstructured":"US Food and Drug Administration Guidance for Industry: Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications; 2010. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/default.htm, accessed 12\/5\/2012."},{"key":"10.1016\/j.vaccine.2014.02.021_bib0020","unstructured":"European Pharmacopoeia Version 7. Tests for extraneous agent in viral vaccines for human use. European Directorate for the Quality of Medicines and HealthCare of the Council of Europe; 2010."},{"key":"10.1016\/j.vaccine.2014.02.021_bib0025","unstructured":"International Conference on Harmonisation\u2014Quality 5D, US Food and Drug Administration; 2012. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm065005.htm, accessed 12\/5\/2012."},{"key":"10.1016\/j.vaccine.2014.02.021_bib0030","unstructured":"US Food and Drug Administration Code of Federal Regulations. Additional standards for viral vaccines. Poliovirus vaccine live oral trivalent. Additional tests for safety. 21 CFR. Part 630.18. Subpart B 1996:97\u201399."},{"key":"10.1016\/j.vaccine.2014.02.021_bib0035","unstructured":"US Food and Drug Administration Code of Federal Regulations. Additional standards for viral vaccines. Measles virus vaccine live. Test for safety. 21 CFR Part 630.35 Subpart D 1996;103\u20135."},{"key":"10.1016\/j.vaccine.2014.02.021_bib0040","unstructured":"US Food and Drug Administration Code of Federal Regulations. Additional standards for viral vaccines. Mumps virus vaccine live. Test for safety. 21 CFR Part 630.55 Subpart F 1996;108."},{"key":"10.1016\/j.vaccine.2014.02.021_bib0045","unstructured":"US Food and Drug Administration Code of Federal Regulations, Additional standards for viral vaccines. Rubella virus vaccine live. Test for safety. 21 CFR Part 630.65 Subpart F 1996;112\u20134."},{"key":"10.1016\/j.vaccine.2014.02.021_bib0050","unstructured":"US Food and Drug Administration Code of Federal Regulations, Good Laboratory Practices. 21 CFR Part 58 2010;p. 306\u201319."},{"key":"10.1016\/j.vaccine.2014.02.021_bib0055","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3181\/00379727-105-26128","article-title":"The vacuolating virus, S.V.40","volume":"105","author":"Sweet","year":"1960","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.vaccine.2014.02.021_bib0060","unstructured":"Update on recommendations for the use of rotavirus vaccines. US Food and Drug Administration; 2010. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm212140.htm, accessed 12\/5\/2012."},{"key":"10.1016\/j.vaccine.2014.02.021_bib0065","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3201\/eid1205.051625","article-title":"Second human case of cache valley virus disease","volume":"12","author":"Campbell","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2014.02.021_bib0070","first-page":"153","article-title":"Detection of adventitious viruses in biologicals a rare occurrence","volume":"123","author":"Nims","year":"2006","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.vaccine.2014.02.021_bib0075","unstructured":"International Conference on Harmonisation\u2014Quality2(R1). US Food and Drug Administration; 2012. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm065005.htm, accessed 12\/5\/2012."},{"key":"10.1016\/j.vaccine.2014.02.021_bib0080","unstructured":"National Institute of Allergy and Infectious Diseases. Vaccine Reagent Resource: http:\/\/www.niaid.nih.gov\/topics\/hivaids\/research\/vaccines\/resources\/reagent\/Pages\/default.aspx, accessed 2\/5\/2012."},{"key":"10.1016\/j.vaccine.2014.02.021_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2013.03.023","article-title":"Opinion on adventitious agents testing for vaccines: why do we worry so much about adventitious agents in vaccines?","author":"Sheets","year":"2013","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14001947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14001947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T17:27:32Z","timestamp":1538760452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14001947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":17,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0264410X14001947"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic evaluation of in vitro and in vivo adventitious virus assays for the detection of viral contamination of cell banks and biological products","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}